Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.37 |
| ▸ | RXRB | P28702 | 4/20 | 0.37 |
| ▸ | RXRG | P48443 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | CCR9 | P51686 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18802726 | 0.90 | CYP1A2 (0.36) | RXRARXRBRXRGCYP1A2CYP2C19 | |
| SCHEMBL2005900 | 0.84 | RXRB (0.50) | RXRARXRBRXRGCYP1A2CYP2C19 | |
| SCHEMBL17022737 | 0.80 | CYP1A2 (0.53) | CYP1A2CYP2C19 | |
| SCHEMBL17022740 | 0.79 | RXRA (0.40) | RXRARXRBRXRGCYP1A2CYP2C19 | |
| SCHEMBL17022729 | 0.78 | RXRA (0.41) | RXRARXRBRXRGCCR9 | |
| SCHEMBL547556 | 0.77 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL6865708 | 0.76 | CES2 (0.52) | RXRARXRBRXRGTACR1 | |
| SCHEMBL548187 | 0.75 | GABRA1 (0.45) | RXRARXRBRXRGCYP1A2GABRA1 | |
| SCHEMBL17022730 | 0.75 | ACE2 (0.31) | — | |
| SCHEMBL21699102 | 0.75 | RXRA (0.54) | RXRARXRBRXRGCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2911002-B1 | RESIST COMPOSITION | MITSUBISHI GAS CHEMICAL CO (JP) | 2019-07-17 | — | — | EP | disclosed |
| US-20180074404-A1 | RADIATION-SENSITIVE COMPOSITION AND METHOD FOR FORMING RESIST PATTERN | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3279731-A1 | RADIATION-SENSITIVE COMPOSITION AND RESIST PATTERN FORMATION METHOD | Mitsubishi Gas Chemical Company, Inc. (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9354516-B2 | Resist composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20150286136-A1 | RESIST COMPOSITION | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-10-08 | — | — | US | disclosed |
| EP-2911002-A1 | RESIST COMPOSITION | Mitsubishi Gas Chemical Company, Inc. (JP) | 2015-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150286136-A1 | RESIST COMPOSITION | SLC11A2, CROCC, PARG | RXRA 1496/4885RXRB 1773/4885RXRG 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.